**Multiple U.S. IPOs are scheduled for mid-October 2026, with Iambic Therapeutics (IAM) and City Therapeutics (CTY) set to price on NASDAQ around October 15-16 at indicative ranges implying roughly $150-200 million raises each.** Recent pricings, including TRex Bio and Retension Pharmaceuticals in early October, confirm active deal flow in biotech and other sectors. Larger candidates such as Anthropic continue targeting a November debut after confidential filings, while earlier 2026 activity (including SpaceX in June) has already established momentum. Equity market conditions, sustained investor demand for AI-adjacent and growth names, and a visible pipeline of S-1 filings support additional listings through year-end. With resolution tied to December 31, 2026, the near-term calendar and recent executions point to high implied probability of completion before 2027.